AccScience Publishing / BH / Online First / DOI: 10.36922/bh.3486
REVIEW ARTICLE

Beyond the gut: Exploring neurological manifestations in inflammatory bowel disease

Manjeet Kumar Goyal1* Shivam Kalra2 Abhinav Rao2 Manisha Khubber3 Abhinav Gupta3 Ashita Rukmini Vuthaluru4
Show Less
1 Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Internal Medicine, Trident Medical Center, North Charleston, South Carolina, United States of America
3 Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
4 Department of Anesthesia and Critical Care, All India Institute of Medical Sciences, New Delhi, India
Brain & Heart 2024, 2(4), 3486 https://doi.org/10.36922/bh.3486
Submitted: 24 April 2024 | Accepted: 27 September 2024 | Published: 30 October 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Neurological manifestations in inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are increasingly recognized as significant contributors to both disease burden and patient morbidity. This comprehensive review delves into the spectrum of neurological complications linked with IBD, highlighting the involvement of both the central and peripheral nervous systems. The neurological impairments range from more common conditions such as peripheral neuropathy, characterized by nerve damage leading to pain and numbness, and cerebrovascular diseases, which include strokes and transient ischemic attacks, to less frequent but intensely severe conditions such as multiple sclerosis and myasthenia gravis, which involve the immune system attacking components of the nervous system. The complex pathophysiology underlying these manifestations integrates various factors including immune-mediated responses, vascular abnormalities such as thromboembolism, nutritional deficiencies often exacerbated by malabsorption and chronic inflammation, and the adverse effects elicited by IBD medications such as corticosteroids and immunomodulators. This review underscores the importance of adopting a multidisciplinary management approach. By integrating the expertise of gastroenterologists with that of neurologists, rheumatologists, and other specialists, patient outcomes can be significantly optimized. Further emphasis is placed on the necessity for heightened clinical awareness and the implementation of early diagnostic interventions to effectively identify and mitigate the neurological complications associated with IBD. In conclusion, ongoing research aimed at elucidating the underlying mechanisms that connect IBD with neurological disorders is imperative to facilitate the development of more effective preventative and therapeutic strategies for these challenging complications.

Keywords
Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
Neurological complications
Immune-mediated mechanisms
Vascular abnormalities
Nutritional deficiencies
Medication adverse effects
Funding
None.
Conflict of interest
The authors declare they have no competing interests.
References
  1. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585-595. doi: 10.1038/nrgastro.2013.117

 

  1. Ferro JM, Oliveira Santos M. Neurology of inflammatory bowel disease. J Neurol Sci. 2021;424:117426. doi: 10.1016/j.jns.2021.117426

 

  1. Benavente L, Morís G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol. 2011;18(1):138-143. doi: 10.1111/j.1468-1331.2010.03095.x

 

  1. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology. 1995;45(3 Pt 1):416-421. doi: 10.1212/wnl.45.3.416

 

  1. Morís G. Inflammatory bowel disease: An increased risk factor for neurologic complications. World J Gastroenterol. 2014;20(5):1228-1237. doi: 10.3748/wjg.v20.i5.1228

 

  1. Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn’s disease. South Med J. 1997;90(6):606-610. doi: 10.1097/00007611-199706000-00005

 

  1. Sassi SB, Kallel L, Ben Romdhane S, Boubaker J, Filali A, Hentati F. Peripheral neuropathy in inflammatory bowel disease patients: A prospective cohort study. Scand J Gastroenterol. 2009;44(10):1268-1269. doi: 10.1080/00365520903199871

 

  1. Oliveira GR, Teles BCV, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14(3):389-395. doi: 10.1002/ibd.20304

 

  1. Geissler A, Andus T, Roth M, et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet. 1995;345(8954):897-898. doi: 10.1016/s0140-6736(95)90013-6

 

  1. Zikou AK, Kosmidou M, Astrakas LG, Tzarouchi LC, Tsianos E, Argyropoulou MI. Brain involvement in patients with inflammatory bowel disease: A voxel-based morphometry and diffusion tensor imaging study. Eur Radiol. 2014;24(10):2499-2506. doi: 10.1007/s00330-014-3242-6

 

  1. Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial. Am Coll Gastroenterol. 2024;119:1365-1372. doi: 10.14309/ajg.0000000000002635

 

  1. Bonaz BL, Bernstein CN. Brain-Gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144(1):36-49. doi: 10.1053/j.gastro.2012.10.003

 

  1. Ferro JM, Oliveira SN, Correia L. Neurologic manifestations of inflammatory bowel diseases. Handb Clin Neurol. 2014;120:595-605. doi: 10.1016/B978-0-7020-4087-0.00040-1

 

  1. Zois CD, Katsanos KH, Kosmidou M, Tsianos EV. Neurologic manifestations in inflammatory bowel diseases: Current knowledge and novel insights. J Crohns Colitis. 2010;4(2):115-124. doi: 10.1016/j.crohns.2009.10.005

 

  1. Babali A, Terzoudi A, Vadikolias K, et al. Peripheral neuropathy electrophysiological screening in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2013;25(5):539- 542. doi: 10.1097/MEG.0b013e32835ceca6

 

  1. Nemati R, Mehdizadeh S, Salimipour H, et al. Neurological manifestations related to Crohn’s disease: A boon for the workforce. Gastroenterol Rep (Oxf). 2019;7(4):291-297. doi: 10.1093/gastro/gox034

 

  1. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014;38:1-12. doi: 10.1016/j.bbi.2013.12.015

 

  1. Didesch MM, Averill A, Oh-Park M. Peripheral neuropathy after fecal microbiota transplantation for Clostridium difficile infection: A case report. PM R. 2016;8(8):813-816. doi: 10.1016/j.pmrj.2016.01.009

 

  1. Romijn JA, Corssmit EP, Havekes LM, Pijl H. Gut-brain axis. Curr Opin Clin Nutr Metab Care. 2008;11(4):518-521. doi: 10.1097/MCO.0b013e328302c9b0

 

  1. Spagnoli C, Pisani F, Di Mario F, et al. Peripheral neuropathy and gastroenterologic disorders: An overview on an underrecognized association. Acta Biomed. 2018;89(Suppl 9):22-32. doi: 10.23750/abm.v89i9-S.7956

 

  1. Gondim FAA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain. 2005;128(Pt 4):867-879. doi: 10.1093/brain/awh429

 

  1. Kim S, Kang SJ, Oh KW, et al. Chronic inflammatory demyelinating polyneuropathy-like neuropathy as an initial presentation of Crohn’s disease. BMC Neurol. 2015;15(1):48. doi: 10.1186/s12883-015-0302-8

 

  1. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin- Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: A systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343-356.e3. doi: 10.1016/j.cgh.2017.06.016

 

  1. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study. Lancet. 2010;375(9715):657-663. doi: 10.1016/S0140-6736(09)61963-2

 

  1. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol. 1979;5(4):331-337. doi: 10.1002/ana.410050405

 

  1. Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and factor V Leiden. QJM. 1997;90(3):183-188. doi: 10.1093/qjmed/90.3.183

 

  1. Goyal MK, Porwal YC, Gogna A, Gulati S. Splenic infarct with scrub typhus: A rare presentation. Trop Doct. 2019;50:234-236. doi: 10.1177/0049475519892092

 

  1. Cognat E, Crassard I, Denier C, Vahedi K, Bousser MG. Cerebral venous thrombosis in inflammatory bowel diseases: Eight cases and literature review. Int J Stroke. 2011;6(6):487-492. doi: 10.1111/j.1747-4949.2011.00620.x

 

  1. Cho JM, Yang HR. Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels of these elements in children newly diagnosed with inflammatory bowel disease. Biol Trace Elem Res. 2018;185(1):20-29. doi: 10.1007/s12011-017-1225-6

 

  1. Casella G, Tontini GE, Bassotti G, et al. Neurological disorders and inflammatory bowel diseases. World J Gastroenterol. 2014;20(27):8764-8782 doi: 10.3748/wjg.v20.i27.8764

 

  1. Lee J, Hwang SW, Lee J, et al. A case of ulcerative colitis presenting with cerebral venous thrombosis. Intest Res. 2018;16(2):306-311. doi: 10.5217/ir.2018.16.2.306

 

  1. Karmiris K, Bossuyt P, Sorrentino D, et al. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. J Crohns Colitis. 2015;9(5):382-389. doi: 10.1093/ecco-jcc/jjv042

 

  1. Oldenburg B, Fijnheer R, van der Griend R, vanBerge- Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: A risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95(10):2825-2830. doi: 10.1111/j.1572-0241.2000.03193.x

 

  1. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-548. doi: 10.1136/gut.2003.025411

 

  1. Stolz E, Klötzsch C, Schlachetzki F, Rahimi A. High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol. 2003;49(4):247-248. doi: 10.1159/000070197

 

 

  1. Pastorelli L, Dozio E, Pisani LF, et al. Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. Gastroenterol Res Pract. 2015;2015:189341. doi: 10.1155/2015/189341
  2. Finnie IA, Shields R, Sutton R, Donnelly R, Morris AI. Crohn’s disease and myasthenia gravis: A possible role for thymectomy. Gut. 1994;35(2):278-279. doi: 10.1136/gut.35.2.278

 

  1. Gower-Rousseau C, Reumaux D, Bellard M, Delecourt L, Ribet M, Colombel JF. Remission of myasthenia gravis after proctocolectomy in a patient with ulcerative colitis. Am J Gastroenterol. 1993;88(7):1136-1138.

 

  1. Foroozan R, Sambursky R. Ocular myasthenia gravis and inflammatory bowel disease: A case report and literature review. Br J Ophthalmol. 2003;87:1186-1187. doi: 10.1136/bjo.87.9.1186

 

  1. Gondim FAA, de Oliveira GR, Araújo DF, Souza MHL, Braga LLB, Thomas FP. Two patients with co-morbid myasthenia gravis in a Brazilian cohort of inflammatory bowel disease. Neuromuscul Disord. 2014;24(11):999-1002. doi: 10.1016/j.nmd.2014.06.434

 

  1. Hayashi K, Kurisu Y, Ohshiba S, et al. Report of a case of Crohn’s disease associated with hyper-creatine phosphokinase-emia. Jpn J Med. 1991;30(5):441-445. doi: 10.2169/internalmedicine1962.30.441

 

  1. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: Emerging mechanisms. Nat Rev Neurol. 2009;5(7):380-391. doi: 10.1038/nrneurol.2009.80

 

  1. Musto AE, Walker CP, Petasis NA, Bazan NG. Hippocampal neuro-networks and dendritic spine perturbations in epileptogenesis are attenuated by neuroprotectin D1. PLoS One. 2015;10(1):e0116543. doi: 10.1371/journal.pone.0116543

 

  1. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15(1):144. doi: 10.1186/s12974-018-1192-7

 

  1. Goyal MK, Singh A, Kumar Gupta Y, Kaur Dhaliwal K, Sood A. Lenvatinib-induced tumor lysis syndrome in advanced hepatocellular carcinoma. ACG Case Rep J. 2023;10(9):e01139. doi: 10.14309/crj.0000000000001139

 

  1. Musto AE, Rosencrans RF, Walker CP, et al. Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism. Sci Rep. 2016;6(1):30298. doi: 10.1038/srep30298

 

  1. De Caro C, Leo A, Nesci V, et al. Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. Sci Rep. 2019;9(1):13983. doi: 10.1038/s41598-019-50542-0

 

  1. Nunes NS, Chandran P, Sundby M, et al. Therapeutic ultrasound attenuates DSS-induced colitis through the cholinergic anti-inflammatory pathway. EBioMedicine. 2019;45:495-510. doi: 10.1016/j.ebiom.2019.06.033

 

  1. Elliott RE, Rodgers SD, Bassani L, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: A consecutive series of 141 cases. J Neurosurg Pediatr. 2011;7(5):491-500. doi: 10.3171/2011.2.PEDS10505

 

  1. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000;75(8):802-806. doi: 10.4065/75.8.802

 

  1. Chen X, Wang S, Mao X, et al. Adverse health effects of emerging contaminants on inflammatory bowel disease. Front Public Health. 2023;11:1140786. doi: 10.3389/fpubh.2023.1140786

 

  1. Cotsapas C, Voight BF, Rossin E, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011;7(8):e1002254. doi: 10.1371/journal.pgen.1002254

 

  1. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129(3):819-826. doi: 10.1053/j.gastro.2005.06.022

 

  1. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 20116;479(7374):538-541. doi: 10.1038/nature10554

 

  1. Banati M, Csecsei P, Koszegi E, et al. Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. Eur J Neurol. 2013;20(11):1492-1495. doi: 10.1111/ene.12072

 

  1. Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;8(8):CD006097. doi: 10.1002/14651858.CD006097.pub3

 

  1. Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A. 2008;105(44):17151-17156. doi: 10.1073/pnas.0806682105

 

  1. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. doi: 10.1056/NEJMoa1606910
Share
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing